Technology, infrastructure and capital are converging to accelerate the commercialization of space-based R&D, underscored by ...

CD22 is a B cell-restricted antigen expressed on many B-cell malignancies and autoreactive B cells, making it a clinically relevant target alternative to CD19. Umoja Biopharma has developed UB-VV400, ...

Scientists from the University of Texas MD Anderson Cancer Center recently reported preclinical comparative evaluation of the ...

The U.S. FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) met to review data from the SYD-101-001 study ...

Bambusa granted underwriters in its IPO a 30-day option to purchase up to an additional 1.6 million shares at the offering ...

Japanese researchers have developed a high speed microscopy technique that captures images so quickly it is possible to ...

Biopharma financings across all categories totaled $29.96 billion in the third quarter (Q3) of 2026, down 14% from $34.8 ...

Driving impressive growth for Eli Lilly and Co., nine-month sales of diabetes and obesity assets Mounjaro and Zepbound (both tirzepatide) are up by 89% and 56%, respectively, over last year, bringing ...

Unlike a single mild traumatic brain injury (TBI), repeated TBI can produce cumulative and long-lasting neurodegeneration, ...

Nonviral gene delivery is expanding beyond traditional approaches, with researchers exploring modified DNA, transposons, circular RNA and polymer-based nanoparticles to achieve durable expression, ...

Financing, IPOs and M&As are three of the biggest drivers of momentum in the med-tech market, and right now the IPO window is ...

Transcripta Bio Inc. and Mayo Clinic have entered into a know-how agreement focused on the molecular characterization of ...